Back to search

Peptide record

TPDB05885

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05885
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0 CAFPdb dbAMP PD_Hemolysis
standard
No
A 9-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
PFWRIRIRR
Physicochemical Analysis
C61H98N22O10
ANDCEQGHLKMSTYV
R
1299.59
12.88
4
0
4
+4
0.09
-0.967
86.67
Mammalian: >20 hour Yeast: >20 hour E.coli: ?
5500
423.21
0
Residue Composition
number
0
A
4
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
0
L
0
K
0
M
1
F
1
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 0 K: 0 M: 0 F: 1 P: 1 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
9
C61H98N22O10
1299.59
12.88
+4
0.09
-0.967
Evidence Records 17 records
Evidence 1 Activity

Activity

2% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
2% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Studies on lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. | J Biol Chem | 2011
Evidence 2 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells. | Sci Rep | 2016
Evidence 3 Activity

Activity

10.4±2.4 Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
10.4±2.4 Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 4 Activity

Activity

14.2±3.5 Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
14.2±3.5 Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 5 Activity

Activity

LC50
Toxicity
>100 µM
Cytotoxic
LC50 | >100 | µM | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine. | Biochim Biophys Acta | 2015
Evidence 6 Activity

Activity

20% Hemolysis
Toxicity
500 µg/mL
Hemolytic Cytotoxic
20% Hemolysis | 500 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Studies on lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. | J Biol Chem | 2011
Evidence 7 Activity

Activity

12.9±1.5 Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
12.9±1.5 Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 8 Activity

Activity

26.1±2.5 Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
26.1±2.5 Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 9 Activity

Activity

16.6±2.4 Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
16.6±2.4 Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 10 Activity

Activity

48.5±5.5 Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
48.5±5.5 Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 11 Activity

Activity

90.1±13.18 Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
90.1±13.18 Hemolysis | 128 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 12 Activity

Activity

15.5±1.2 Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
15.5±1.2 Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 13 Activity

Activity

36.1±2 Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
36.1±2 Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 14 Activity

Activity

83.2±23 Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
83.2±23 Hemolysis | 128 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 15 Activity

Activity

12.9±1.2 Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
12.9±1.2 Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 16 Activity

Activity

31.8±3.14 Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
31.8±3.14 Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Blood Compatibility-An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application. | Int J Mol Sci | 2019
Evidence 17 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis